X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with ALEMBIC PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs ALEMBIC PHARMA - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. ALEMBIC PHARMA FRESENIUS KABI ONCO./
ALEMBIC PHARMA
 
P/E (TTM) x 22.1 28.9 76.5% View Chart
P/BV x 3.1 6.6 47.2% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 FRESENIUS KABI ONCO.   ALEMBIC PHARMA
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
ALEMBIC PHARMA
Mar-16
FRESENIUS KABI ONCO./
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs176792 22.2%   
Low Rs79443 17.7%   
Sales per share (Unadj.) Rs37.7167.0 22.6%  
Earnings per share (Unadj.) Rs5.138.2 13.3%  
Cash flow per share (Unadj.) Rs6.742.0 16.0%  
Dividends per share (Unadj.) Rs04.00 0.0%  
Dividend yield (eoy) %00.6 0.0%  
Book value per share (Unadj.) Rs42.584.9 50.1%  
Shares outstanding (eoy) m158.23188.52 83.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.43.7 91.4%   
Avg P/E ratio x25.016.2 154.4%  
P/CF ratio (eoy) x18.914.7 128.7%  
Price / Book Value ratio x3.07.3 41.1%  
Dividend payout %010.5 0.0%   
Avg Mkt Cap Rs m20,135116,383 17.3%   
No. of employees `0001.2NA-   
Total wages/salary Rs m7034,214 16.7%   
Avg. sales/employee Rs Th5,176.2NM-  
Avg. wages/employee Rs Th610.4NM-  
Avg. net profit/employee Rs Th699.6NM-  
INCOME DATA
Net Sales Rs m5,96331,487 18.9%  
Other income Rs m1855 32.7%   
Total revenues Rs m5,98131,542 19.0%   
Gross profit Rs m1,43010,060 14.2%  
Depreciation Rs m258722 35.7%   
Interest Rs m-2637 -70.7%   
Profit before tax Rs m1,2169,356 13.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-2 0.0%   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m3422,160 15.8%   
Profit after tax Rs m8067,194 11.2%  
Gross profit margin %24.031.9 75.1%  
Effective tax rate %28.123.1 121.9%   
Net profit margin %13.522.8 59.2%  
BALANCE SHEET DATA
Current assets Rs m5,10215,066 33.9%   
Current liabilities Rs m2,3857,674 31.1%   
Net working cap to sales %45.623.5 194.0%  
Current ratio x2.12.0 108.9%  
Inventory Days Days15067 224.1%  
Debtors Days Days11341 278.8%  
Net fixed assets Rs m5,1488,237 62.5%   
Share capital Rs m158377 42.0%   
"Free" reserves Rs m6,55615,416 42.5%   
Net worth Rs m6,73216,005 42.1%   
Long term debt Rs m9520-   
Total assets Rs m10,38824,594 42.2%  
Interest coverage x-45.8255.2 -17.9%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.61.3 44.8%   
Return on assets %7.529.4 25.5%  
Return on equity %12.044.9 26.6%  
Return on capital %14.658.7 24.9%  
Exports to sales %74.555.7 133.6%   
Imports to sales %24.810.4 237.6%   
Exports (fob) Rs m4,44117,551 25.3%   
Imports (cif) Rs m1,4773,283 45.0%   
Fx inflow Rs m5,29817,811 29.7%   
Fx outflow Rs m1,7725,318 33.3%   
Net fx Rs m3,52512,493 28.2%   
CASH FLOW
From Operations Rs m1,2749,304 13.7%  
From Investments Rs m-1,204-3,105 38.8%  
From Financial Activity Rs m-196-1,959 10.0%  
Net Cashflow Rs m-1264,240 -3.0%  

Share Holding

Indian Promoters % 0.0 74.1 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 2.9 10.3%  
FIIs % 9.6 9.1 105.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 13.9 65.5%  
Shareholders   42,599 49,328 86.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   ORCHID PHARMA LTD  WYETH LTD  ABBOTT INDIA  ALEMBIC LTD  DR. REDDYS LAB  

Compare FRESENIUS KABI ONCO. With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Day Flat; Oil and Gas Stocks Lead Losses(Closing)

After opening the day in red, share markets in India witnessed negative trading activity throughout the day and ended the day on a weak note.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. - GSK PHARMA COMPARISON

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS